A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4-6 Weeks Exposure to Immune-Attractant
Latest Information Update: 13 Apr 2022
At a glance
- Drugs Durvalumab (Primary) ; Exemestane (Primary) ; Tremelimumab (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms ULTIMATE
- 29 Sep 2020 Status changed from active, no longer recruiting to completed.
- 05 Sep 2020 This trial has been completed in France, according to European Clinical Trials Database record.
- 02 Oct 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Jan 2020.